These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 1938685)

  • 41. Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments.
    Skarp KP; Shams A; Montelin H; Lagerbäck P; Tängdén T
    Int J Antimicrob Agents; 2019 Jan; 53(1):74-79. PubMed ID: 30236958
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Resistance to amoxicillin and amoxicillin-clavulanic acid combination of 231 clinical strains of Escherichia coli, isolated in 1992 at the Cochin Hospital].
    Bémer-Melchior P; Gilly L; Jugroot-Klotz K; Brun T; Névot P; Paul G
    Pathol Biol (Paris); 1995 Nov; 43(9):760-5. PubMed ID: 8746097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
    Docobo-Pérez F; Fernández-Cuenca F; Pachón-Ibáñez ME; Pascual A; Pichardo C; Martínez-Martínez L; Pachón J
    Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular characterization of amoxicillin-clavulanate resistance in a clinical isolate of Escherichia coli.
    Bellaaj A; Bollet C; Alfeddy N; Limam F; Belhadj C; Regli A; Chollet R; Belhadj O; Ben-Mahrez K
    Microb Drug Resist; 2002; 8(4):267-72. PubMed ID: 12523623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A combination of mecillinam and amoxicillin/clavulanate can restore susceptibility of high-level TEM-1-producing Escherichia coli to mecillinam.
    Birgy A; Delecourt M; Geslain G; Desselas E; Caseris M; Magnan M; Mariani-Kurkdjian P; Bidet P; Bonacorsi S
    J Antimicrob Chemother; 2017 Jul; 72(7):1911-1914. PubMed ID: 28369441
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Combinations of beta-lactamase inhibitors and semisynthetic penicillins: amoxycillin/clavulanic acid (augmentin, amox-clav ), thycarcillin/clavulanic acid (thymentin). Action and usage].
    Fomina IP
    Antibiot Khimioter; 1997; 42(12):29-32. PubMed ID: 9480651
    [No Abstract]   [Full Text] [Related]  

  • 47. Activity of amoxycillin/clavulanic acid against Escherichia coli in vivo--correction.
    Beale AS
    J Antimicrob Chemother; 1992 Jul; 30(1):108. PubMed ID: 1429330
    [No Abstract]   [Full Text] [Related]  

  • 48. An in-vitro and in-vivo comparison of the activity of beta-lactamase inhibitor combinations with imipenem and cephalosporins against Escherichia coli producing TEM-1 or TEM-2 beta-lactamase.
    Cherubin CE; Eng RH; Smith SM; Tan EN
    J Antimicrob Chemother; 1991 Jul; 28(1):61-70. PubMed ID: 1769944
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potential effects of amoxycillin/clavulanic acid and ticarcillin/clavulanic acid on human granulocyte activity: a comparative study.
    Cuffini AM; Tullio V; Paizis G; Carlone NA
    J Antimicrob Chemother; 1996 Dec; 38(6):1013-22. PubMed ID: 9023648
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ticarcillin/clavulanate in the treatment of pelvic infections.
    Lucas MJ; Cox SM; Roark ML; Cunningham FG
    J Reprod Med; 1990 Mar; 35(3 Suppl):343-7. PubMed ID: 2181121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implications of beta-lactamase-inhibitor combinations.
    Fuchs PC; Barry AL
    J Reprod Med; 1990 Mar; 35(3 Suppl):317-21. PubMed ID: 2319514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Antimicrobial activities of clavulanic acid/ticarcillin against clinical isolates].
    Koguchi M; Suzuki Y; Tanaka S; Fukayama S; Ishihara R; Deguchi K; Oda S; Nakane Y; Fukumoto T
    Jpn J Antibiot; 1995 Dec; 48(12):1899-905. PubMed ID: 8587164
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
    Leclercq R; Duval J
    Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resistance to amoxicillin/clavulanate in Escherichia coli.
    Colaert J
    Acta Clin Belg; 1992; 47(5):353-4. PubMed ID: 1334324
    [No Abstract]   [Full Text] [Related]  

  • 55. In vitro anaerobic data on ticarcillin/clavulanate. A review of an ongoing survey.
    Sanders CV; Aldridge KE
    J Reprod Med; 1990 Mar; 35(3 Suppl):313-6. PubMed ID: 2319513
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of extended broad-spectrum beta-lactamases in Enterobacteriaceae in four French hospitals.
    Legrand P; Fournier G; Buré A; Jarlier V; Nicolas MH; Decré D; Duval J; Philippon A
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):527-9. PubMed ID: 2504594
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clavulanate and beta-lactamase induction.
    Livermore DM; Akova M; Wu PJ; Yang YJ
    J Antimicrob Chemother; 1989 Nov; 24 Suppl B():23-33. PubMed ID: 2606817
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Back mutations to the TEM-1 beta-lactamase from TRC-1 lead to restored sensitivity to clavulanic acid.
    Thomson CJ; Amyes SG
    J Med Microbiol; 1995 Jun; 42(6):429-32. PubMed ID: 7791208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ex vivo pharmacodynamics of amoxicillin-clavulanate against beta-lactamase-producing Escherichia coli in a yucatan miniature pig model that mimics human pharmacokinetics.
    Bronner S; Murbach V; Peter JD; Levêque D; Elkhaïli H; Salmon Y; Dhoyen N; Monteil H; Woodnutt G; Jehl F
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3782-9. PubMed ID: 12435677
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modified Antibiotic Adjuvant Ratios Can Slow and Steer the Evolution of Resistance: Co-amoxiclav as a Case Study.
    Allen RC; Brown SP
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.